Atrys Health SA (ES:ATRY) has released an update.
Atrys Health SA has reported a strong first half in 2024, with revenues increasing by 5% to 107.4 million euros and adjusted EBITDA rising by 24.6% to 25.3 million euros. The company attributes its growth to advancements in all business areas, especially oncology, and is on track to meet its annual guidance of 220-224 million euros in turnover and 47-49 million in adjusted EBITDA. Significant growth in the Latin American market and the expansion of medical oncology centers in Mexico are highlighted as key contributors to Atrys’ financial success.
For further insights into ES:ATRY stock, check out TipRanks’ Stock Analysis page.
